15441-07-3

Basic information

• Product Name: 3-Chlorosulfonyl-propionic acid methyl ester
• Synonyms: 3-Chlorosulfonyl-propionic acid methyl ester;Methyl 3-chlorosulfonylpropionate;3-Methoxy-3-oxopropanesulfonyl chloride
• CAS NO: 15441-07-3
• Molecular Formula: C₄H₇ClO₄S
• Molecular Weight: 186.61398
• Mol File: 15441-07-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 245.7°Cat760mmHg
• Flash Point: 102.4°C
• Appearance: /
• Density: 1.43g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-Chlorosulfonyl-propionic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Chlorosulfonyl-propionic acid methyl ester(15441-07-3)
• EPA Substance Registry System: 3-Chlorosulfonyl-propionic acid methyl ester(15441-07-3)

Safety Data

• Hazardous Substances Data: 15441-07-3(Hazardous Substances Data)

Usage

General Description

3-Chlorosulfonyl-propionic acid methyl ester is a chemical compound used in the pharmaceutical industry for the synthesis of various drugs and biologically active molecules. It is an ester of 3-chlorosulfonyl-propionic acid and methyl alcohol, and it is known for its strong electrophilic and nucleophilic properties. 3-Chlorosulfonyl-propionic acid methyl ester is commonly utilized as an intermediate in the production of pharmaceuticals, agrochemicals, and other fine chemicals. Its reactivity and functional groups make it a valuable building block for organic synthesis, providing a platform for the creation of diverse chemical structures with potential applications in medicine and agriculture. Additionally, it is a key component in the development of new synthetic strategies and drug discovery efforts.

Upstream product

• 71562-00-0 3-sulfo-propionic acid methyl ester 
• 2935-90-2 Methyl 3-mercaptopropionate 
• 29652-02-6 3-thiocyanatopropionic acid methyl ester 

Downstream Products

• 856811-63-7 3,3'-(2,4,6-trimethyl-m-phenylenedisulfamoyl)-di-propionic acid dimethyl ester 
• 15441-08-4 methyl 3-sulfamoylpropanoate 
• 1257867-16-5 C₄₇H₆₃NO₇S 
• 90030-48-1 sodium 3-methoxy-3-oxo-propane-1-sulfinate 
• 1325189-88-5 C₁₁H₁₄BrNO₅S 
• 1070668-74-4 N-(2-fluoro-6-cinnamylbenzyl)-2-methoxycarbonylethanesulfonamide 
• 1048041-28-6 3-[11-(4-(benzyloxy)-2-chlorophenyl)-6-hydroxy-3,3-dimethyl-1-oxo-1,2,3,4,5,11-hexahydrodibenzo[b,e][1,4]diazepine-10-sulfonyl]propionic acid methyl ester 
• 423767-62-8 3-{4-[4-((S)-2-Methyl-1-phenyl-propylcarbamoyl)-2-phenyl-quinolin-3-ylmethyl]-piperazine-1-sulfonyl}-propionic acid methyl ester 
• 189012-92-8 methyl 3-[2-(2-phenylthioethoxy)ethylaminosulphonyl]propanoate 
• 189012-84-8 methyl 3-[2-(2-phenyl-1-propoxy)ethylaminosulphonyl]propanoate 
• 189012-77-9 methyl 3-[2-[2-(4-methylphenyl)ethoxy]ethylaminosulphonyl]propanoate 
• 189012-23-5 Methyl 3-[2-(2-phenylethoxy)ethylaminosulphonyl]propanoate 
• 137383-68-7 3-[N-(4-Fluoro-2-trifluoromethylphenyl)sulfamoyl]propionic Acid Methyl Ester 
• 111874-98-7 3-[2-(3-Chloro-phenyl)-ethylsulfamoyl]-propionic acid methyl ester 

Relevant articles and documents

Iridinesulfonamide compound and use method thereof

An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically-acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation-induced cancers.

INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1

The compounds of formula (I) are derived from perhydroquinoline and perhydroisoquinoline and are useful as active pharmaceutical ingredients for the prophylaxis or treatment of diseases caused by 11-beta-hydroxysteroid dehydrogenase type I (11-beta-HSD1) enzyme-associated disorders, such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, Cushing's syndrome, psoriasis, rheumatoid arthritis, cognitive disorders, Alzheimer's disease or neurodegeneration.

AMINOALCOHOL DERIVATIVES

The present invention relates to a compound of the formula [I]: wherein (a), in which -Y-, R4, R5 and R6 are4 R5each as defined in the description, etc., R1 is hydrogen, halogen, lower alkyl, hydroxy, etc., R2 is hydrogen, lower alkyl or hydroxy(lower)alkyl, R3 is hydrogen or an amino protective group, 20 R7 is hydrogen, lower alkyl, cyclo(lower)alkyl, lower R9 alkenyl, -Z-R9 or (b), in which -Z- is -0-, -S-, R9 -SO- or -SO2-, and each R9 is independently hydrogen, lower alkyl, cyclo(lower)alkyl, etc., and R8 is -D-E-R10, in which -D- is -CONHSO2- or -S02NHCO-, E is bond or lower alkylene, and R10is halogen, cyano, carboxy, etc., or a prodrug thereof or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of ulcer, overactive bladder, and the like.